| SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Diagnosis and classification of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Alternative donor transplantation for severe aplastic anemia: a comparative study of the SAAWP EBMT |
|
Blood |
Aplastic Anemia |
| The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
|
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
